Patents by Inventor Patrick Secor

Patrick Secor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibody and vaccine targeting filamentous bacteriophage
    Patent number: 11911472
    Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: February 27, 2024
    Assignee: INIMMUNE CORPORATION
    Inventors: Paul L. Bollyky, William Parks, Patrick Secor
  • MONOCLONAL ANTIBODY AND VACCINE TARGETING FILAMENTOUS BACTERIOPHAGE
    Publication number: 20210030875
    Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: February 4, 2021
    Inventors: Paul L. Bollyky, William Parks, Patrick Secor
  • Monoclonal antibody and vaccine targeting filamentous bacteriophage
    Patent number: 10835607
    Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: November 17, 2020
    Assignee: INIMMUNE CORPORATION
    Inventors: Paul L. Bollyky, William Parks, Patrick Secor
  • MONOCLONAL ANTIBODY AND VACCINE TARGETING FILAMENTOUS BACTERIOPHAGE
    Publication number: 20200038510
    Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
    Type: Application
    Filed: January 30, 2019
    Publication date: February 6, 2020
    Inventors: Paul L. Bollyky, William Parks, Patrick Secor
  • MONOCLONAL ANTIBODY AND VACCINE TARGETING FILAMENTOUS BACTERIOPHAGE
    Publication number: 20170021020
    Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
    Type: Application
    Filed: July 25, 2016
    Publication date: January 26, 2017
    Inventors: Paul L. Bollyky, William Parks, Patrick Secor